TITLE

Stability of extemporaneously prepared rifaximin oral suspensions

AUTHOR(S)
COBER, MARY PETREA; JOHNSON, CARY E.; LEE, JORDAN; CURRIE, KENNE
PUB. DATE
February 2010
SOURCE
American Journal of Health-System Pharmacy;2/15/2010, Vol. 67 Issue 4, p287
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The stability of extemporaneously prepared rifaximin oral suspensions was studied. Methods. An oral suspension of rifaximin 20 mg/mL was prepared by thoroughly grinding six 200-mg tablets of rifaximin in a glass mortar. Thirty milliliters of Ora-Plus and 30 mL of either Ora-Sweet or Ora-Sweet SF were mixed and added to the powder to make a final volume of 60 mL. Three identical samples of each formulation were prepared and placed in 2-oz amber plastic bottles with child-resistant caps and were stored at room temperature (23-25 °C). A 1-mL sample was withdrawn from each of the six bottles with a micropipette immediately after preparation and at 7, 15, 30, and 60 days. After further dilution to an expected concentration of 20 mg/mL with mobile phase, the samples were assayed in duplicate using stability-indicating high-performance liquid chromatography. The samples were visually examined for any color change and pH was tested on each day of analysis. Stability was determined by evaluating the percentage of the initial concentration remaining at each time point and defined as retention of at least 90% of the initial concentration of rifaximin. Results. At least 99% of the initial rifaximin remained throughout the 60-day study period in both preparations. There were no detectable changes in color, odor, taste, or pH and no visible microbial growth in any sample. Conclusion. Extemporaneously prepared suspensions of rifaximin 20 mg/mL in 1:1 mixtures of Ora-Plus with either Ora-Sweet or Ora-Sweet SF were stable for at least 60 days when stored in 2-oz amber plastic bottles at room temperature.
ACCESSION #
47923919

 

Related Articles

  • Hard-to-open medicine caps.  // Current Health 2;Oct96, Vol. 23 Issue 2, p2 

    Reports on the result of a study indicating that child-resistant medicine caps have saved hundreds of young lives since the United States government began requiring them in 1974.

  • Child-resistant packaging.  // FDA Consumer;Oct96, Vol. 30 Issue 8, p29 

    Reports on research findings indicating that child-resistant packaging has saved hundreds of lives since it was mandated for oral prescription drugs in 1974. Researcher Gregory Rodgers' article published in the `Journal of American Medical Association.'

  • Did you know...that child-resistant drug packaging saves lives?  // People's Medical Society Newsletter;Dec96, Vol. 15 Issue 6, p8 

    Reports on the findings of a new study by a US Consumer Product Safety Commission researcher, which shows that child-resistant packaging requirements for prescription drugs have saved the lives of children since they were implemented in 1974. Difficulty for children to open child-resistant drug...

  • MATERIALS.  // Food & Drug Packaging;Feb2007, Vol. 71 Issue 2, p68 

    The article offers information about several packaging materials including the 53-millimeter child-resistant closure from Rexam Closures & Containers, the polyethylene terephthalate Boston Rounds from Alpha Packaging and the Flavorseal BGB-90 Bone Guard Shrink Bag from Caroll Manufacturing & Sales.

  • CRCs Now Mandated. Gefken, Carl // Global Cosmetic Industry;Dec2001, Vol. 169 Issue 7, p10 

    Reports the passage of the Child-Resistant Closure Rule in the United States. Coverage of the legislation; Impact of the death of 16-month-old Jason Bryson on the passage of the bill; Provisions of the regulation.

  • Expanding the Use of Child-Resistant Packaging. Forcinio, Hallie // Pharmaceutical Technology North America;May2002, Vol. 26 Issue 5, p24 

    Focuses on the standards and regulations for child-resistant (CR) packaging for drugs in the U.S. Efforts to save children from traumatic experiences, injury and death; Compliance issues for CR packaging requirements; Concerns on the costly process of packaged designs.

  • Cap it.  // Drug Topics;3/20/95, Vol. 139 Issue 6, p20 

    Reports on the alliance between Healthcare Compliance Packaging Council and the Coalition for Responsible Packaging to oppose the proposed changes in testing of child-resistant packaging. Consumer Product Safety Commission's proposal.

  • Vial/blister eas es Dramamine access.  // Packaging Digest;Jan97, Vol. 34 Issue 1, p54 

    Introduces Dramamine in the new child-resistant and tamper evident vial. Features of the product; Vial graphic designs; Package' color patterns.

  • Boxing out. Fogarty, Beth G. // Beverage World;Jun95, Vol. 114 Issue 1593, p72 

    Focuses on the efforts of the American aseptic carton industry to increase its share in the beverage packaging market. Maturity of the industry from a child-resistant packaging strategy into other capabilities; Emphasis on recloseability or resealability features of cartons; Vertical linkage of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics